Kops group in Nature Genetics

Scientists at The Institute of Cancer Research in London together with the Geert Kops group published a paper in Nature Genetics today, titled “Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation”. The study is about the discovery of a new genetic cause of kidney cancer in children.

The Kops group, together with scientists at The Institute of Cancer Research in London, has identified a new genetic cause of a childhood kidney cancer called Wilms tumour – revealing insights into how loss of control of chromosome number can lead to cancer. Their study will help parents understand why their children have developed cancer, and provide information about the risk of cancer for other children. It has also provided valuable information about the fundamental biology of cancer, by shedding new light on how the disease may be linked to disruptions to the process for sorting chromosomes between cells when cells divide.

Wilms tumor

The research group studied families with a rare genetic syndrome that affects chromosome number to try to identify mutations linked to Wilms tumour. Wilms tumour affects about 1 in 10,000 children, but fortunately is curable in about 90% of children. It has been linked to several different genetic syndromes, one of which is called ‘mosaic variegated aneuploidy (MVA) syndrome’. Children with MVA syndrome have cells with the wrong number of chromosomes, a condition called aneuploidy. Some cells have too many chromosomes whilst others have too few. Researchers used a technique called exome sequencing to analyse all the genes in 20 families with MVA. They discovered mutations in a gene called TRIP13 in three of them. Interestingly the data suggested that ancestors of all three children originated from the Azad Kashmir region of Pakistan. Next, the researchers looked at UK children with Wilms tumour with ancestors from Azad Kashmir, but without MVA, and found two with the same TRIP13 mutations. They also identified a child from Norway with Wilms tumour caused by different TRIP13 mutations.

Duplication machinery

When a cell divides into two cells the 23 pairs of chromosomes are first duplicated and then split up so that each new cell has 23 pairs of chromosomes. This process is very tightly controlled, because if anything goes wrong cells can end up with the wrong number of chromosomes. TRIP13 codes for one of the essential proteins in machinery involved in checking that chromosomes are all lined up correctly ready to be sorted into the new cells before cell division starts. The researchers previously showed that BUB1B, another essential gene in this process, is also linked to MVA and childhood cancer. Aneuploidy is a hallmark of cancer cells, so it is not so surprising that children with MVA are also at risk of cancer. However, the researchers showed that not all children with MVA are at high risk of cancer. Children with MVA due to BUB1B or TRIP13 mutations are at high cancer risk, particularly of Wilms tumour. But, children with MVA due to other causes, or in whom the cause is currently unknown, were not at high risk of childhood cancer in this study. This is important because it suggests that the underlying mechanism leading to aneuploidy rather than simply having the wrong number of chromosomes that is important in cancer.

Collaboration

The study leader, Professor Nazneen Rahman, Head of Genetics at The Institute of Cancer Research, London, said: “This study has been of immediate use to families in providing a reason for why their child developed cancer, and information about risks to other children, which is very rewarding. Equally importantly the study has provided new information about how aneuploidy and cancer are linked – a topic that has been hotly debated and intensively researched for many decades.”

Co-study lead Dr Geert Kops, said: “This was a gratifying collaboration as it allowed us to focus our molecular expertise towards understanding the cause of cancer in children and it has also driven forward our research into the control of chromosome segregation.”

The study was funded by Wellcome, the Netherlands Organisation for Scientific Research and the Dutch Cancer Society.

Read the whole study here